Similarly, polymorphisms in 17-beta hydroxysteroid dehydrogenase 13 (HSD17B13), which is involved in lipid droplet dynamics, appear to have protective effects against MASLD progression, particularly in reducing inflammation and fibrosis risk. The gene discussed is HSD17B13; the disease is metabolic dysfunction-associated steatotic liver disease.